These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37734807)

  • 1. Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Shahmanesh M; Hargreaves JR; Smith J; Revill P; Sibanda E; Ehrenkranz P; Sikwese K; Rodger A; Lundgren JD; Gilks CF; Godfrey C; Cowan F; Cambiano V
    Lancet Glob Health; 2023 Oct; 11(10):e1648-e1657. PubMed ID: 37734807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
    Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
    Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
    Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
    Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.
    Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P
    J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models.
    Bansi-Matharu L; Mudimu E; Martin-Hughes R; Hamilton M; Johnson L; Ten Brink D; Stover J; Meyer-Rath G; Kelly SL; Jamieson L; Cambiano V; Jahn A; Cowan FM; Mangenah C; Mavhu W; Chidarikire T; Toledo C; Revill P; Sundaram M; Hatzold K; Yansaneh A; Apollo T; Kalua T; Mugurungi O; Kiggundu V; Zhang S; Nyirenda R; Phillips A; Kripke K; Bershteyn A
    Lancet Glob Health; 2023 Feb; 11(2):e244-e255. PubMed ID: 36563699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
    Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
    Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.
    Laurent C; Dembélé Keita B; Yaya I; Le Guicher G; Sagaon-Teyssier L; Agboyibor MK; Coulibaly A; Traoré I; Malan JB; De Baetselier I; Eubanks A; Riegel L; Rojas Castro D; Fayé-Ketté H; Koné A; Diandé S; Dagnra CA; Serrano L; Diallo F; Mensah E; Dah TTE; Anoma C; Vuylsteke B; Spire B;
    Lancet HIV; 2021 Jul; 8(7):e420-e428. PubMed ID: 34048794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
    Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the Uptake and Outcomes of Non-occupational Postexposure Prophylaxis Use Through an Online Medical Platform in China: Web-Based Cross-sectional Study.
    Shan D; Xue H; Yu F; Zan X; Liu H; Liu J; Han M; Zhang D
    J Med Internet Res; 2023 May; 25():e42729. PubMed ID: 37204828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
    Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB
    PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
    Kouamou V; Machekano R; Mapangisana T; Maposhere C; Munyati S; Mutsvangwa J; Shamu T; McCarty K; Katzenstein D; Manasa J
    AIDS Res Hum Retroviruses; 2022 Oct; 38(10):774-778. PubMed ID: 35959737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
    Semengue ENJ; Fokam J; Etame NK; Molimbou E; Chenwi CA; Takou D; Mossiang L; Meledie AP; Yagai B; Nka AD; Dambaya B; Teto G; Ka'e AC; Beloumou GA; Djupsa Ndjeyep SC; Abba A; Kengni AMN; Tommo Tchouaket MC; Bouba NP; Billong SC; Sosso SM; Colizzi V; Perno CF; Kouanfack C; Zoung-Kanyi Bissek AC; Eben-Moussi E; Santoro MM; Ceccherini-Silberstein F; Ndjolo A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.